Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-007 - Phase I study of the ALK inhibitor LDK378 in Japanese patients with advanced, ALK-rearranged NSCLC and other tumors harboring genetic ALK alterations
09:30 - 09:30 | Author(s): T. Seto
- Abstract
Loading...
-
+
P2.01 - Poster Session 2 - Cancer Biology
- Type: Poster Session
- Track: Biology
- Presentations: 26
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.01-007 - Distinct characteristics of small cell lung cancer (SCLC) correlate with central or peripheral origin - microarray analysis of snap frozen tissue samples.
09:30 - 09:30 | Author(s): E. Miyauchi
- Abstract
Loading...
-
+
P2.09 - Poster Session 2 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.09-006 - Long-term results of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Naito
- Abstract
Loading...
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-012 - Phase Ia/Ib study of the anti-MET antibody onartuzumab (MetMAb) in patients with solid tumors or MET-positive lung cancer
09:30 - 09:30 | Author(s): H. Horinouchi
- Abstract
Loading... -
+
P2.11-020 - Sorafenib in patients with RET fusion-positive non-small cell lung cancer
09:30 - 09:30 | Author(s): A. Horiike
- Abstract
Loading...
-
+
O15 - NSCLC - Chemotherapy II
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:G. Richardson
- Coordinates: 10/29/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
O15.05 - Randomized Phase III Trial of S-1 plus Cisplatin versus Docetaxel plus Cisplatin for Advanced Non-Small-Cell Lung Cancer (TCOG0701): Subgroup Analysis.
11:15 - 11:25 | Author(s): O. Ishimoto
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.05 - Efficacy, safety, and patient-reported outcomes (PROs) with crizotinib versus chemotherapy in Asian patients in a phase III study of previously treated advanced ALK-positive non-small cell lung cancer (NSCLC)
11:15 - 11:25 | Author(s): M. Nishio
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-010 - Patterns of relapse and prognosis after crizotinib therapy failure in ALK+ Non-small cell lung cancer
09:30 - 09:30 | Author(s): N. Yanagitani
- Abstract
Loading... -
+
P3.11-034 - One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Inoue
- Abstract
Loading...
-
+
MO21 - Prognostic and Predictive Biomarkers V - EGFR
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:D.C. Lam
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
MO21.03 - Variability of epidermal growth factor receptor (EGFR) mutations in serum during erlotinib therapy and its clinical implications: exploratory analysis of a phase II study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations
10:40 - 10:45 | Author(s): M. Maemondo
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.